CClinicalTrials.gg
Status unknownNCT04836598Updated Apr 8, 2021

Bikini Scarless Laparoscopic Cholecystectomy for Morbid Obesity as a Day Case.

An interventional study of laparoscopic cholecystectomy in Cholecystitis, Chronic, sponsored by Zagazig University. Status unknown at 4 sites in 2 countries. Open to participants aged 17 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-04-08.

Sponsored by Zagazig University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2021), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 years 4 months after the study started (first participant enrolled Nov 2016, registered Mar 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
17 Years to 65 Years
Sex
All
01

Study summary

Background: Bikini line laparoscopic cholecystectomy is a safe method, used as a scarless cosmetic port technique for gall bladder diseases in morbid obese patients as a day case.

Objectives:

The aim of this study was to investigate the safety and efficacy of an elective Bikini line laparoscopic cholecystectomy in the morbid obese patients with chronic calcular cholecystitis, and review our experience with Bikini line laparoscopic cholecystectomy as minimal invasive scarless technique.

We issued a modifications in order to minimize the number of ports (Brief ports) and modify port sites, using the Bikini line laparoscopic cholecystectomy as a cosmetic and hidden scar laparoscopy for obese patients concerned with aesthetic results and body image. Aiming at faster recovery, decrease pain and improve cosmoses.

Bikini Line laparoscopic cholecystectomy is technically safe and effective day surgery procedure for chronic cholecystitis patients with higher patient satisfaction regarding pain and cosmoses. Obesity, intended as BMI 40, does not have any obstacle on the technical feasibility of BLLC.

Read the detailed description

Thoroughly, BLLC is a novel technique aimed at solving the issue of cosmoses that is always presented as a main complaint from morbid obese patients. The main concern to use Brief ports laparoscopy or hidden scar laparoscopy to reduce incisions and change sites. The study designed to identify superiority of technique regarding success as a day case surgery, better cosmoses and lesser pain.

We tried to wear off the port sites scar and kept our stabs in the suprapubic Bikin line. We kept camera port in the navel's natural scar and used the other ports in lower abdominal crease at Bikini line. Cosmosis has been and still the reason among patient population to accept the laparoscopic surgery, many synonyms can be applied here, as Cosmotic,Hidden scar, Scarless, Non-visualized or Scarless Bikini cholecystectomy.

BLLC is performed under general anesthesia. Patient placed in the supine position with patient's legs apart and arms are rolled in, patient strapped to table at the mid-thigh. Surgeon stood between patient's legs, the camera man stood on the right side of patient, monitor placed near patient head to the right side. Three ports were used, 12 mm visiport (....) umbilical, with A 30 degree camera used, 5mm in Bikini line at Right mid-clavicular line and third port 5mm in Bikini line at left mid-clavicular line (Figure) Patient kept in reverse Trendlenburg position with maximum degree 20. But to lesser degree than done in classic LC,

02

Conditions studied

  • Cholecystitis, Chronic

Keywords

  • scarless cholecystectomy
  • Breif port cholecystectomy
03

In context

Cholecystitis

266 studies on the registry are indexed under Cholecystitis; 46 are open to participants now.

This study's planned enrollment of 3 is below the median of 86 across 167 interventional studies indexed under Cholecystitis.

Browse Cholecystitis studies →

Lead sponsor

Zagazig University is the lead sponsor of 447 studies on the registry; 75 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Morbid obese patients with BMI ≤30 KG/M2 and ≥ 40 9kg/m2 with symptomatic uncomplicated gall stones, ASA 1-3.

Exclusion criteria

Exclusion Criteria:

  • Acute calcular cholecystitis, BMI ≥45, ASA 4 or higher, length of stay more than 1 day.

Patients required additional trocars for patient safety, readmission,

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (estimated)

Study arms

  • Active comparator
    Multiport laparoscopic cholecystectomy

    controlled group

    Other: laparoscopic cholecystectomy

  • Active comparator
    Bikini line laparoscopic cholecystectomy

    bikini line 2 ports

    Other: laparoscopic cholecystectomy

Interventions

  • Otherlaparoscopic cholecystectomy

    A Prospective randomized controlled trial study was undertaken along 4 years Between November 2016 and October 2020, in two institutions. 400 patients were selected, 200 patients underwent BLLC and 200 patients underwent multiple port laparoscopic cholecystectomy (MPLC).

    Also known as: brief port scarless laparoscopic cholecystectomy

06

What researchers measure

Primary outcomes

  1. a successful and safe day case

    a successful and safe day case laparoscopic cholecystectomy with discharge on the same day with no significant pain. patient stayed more than a day was not enrolled

    Time frame: 4 years

Secondary outcomes

  1. Measured patient satisfaction from body image and cosmoses within 6 months from surgery.

    Postoperative pain was defined as mild, moderate sever according to visual analogue scale (VAS) Pain assessment at the tommy and at port sites were assessed at postoperative day 1 and at discharge as follow, 8 hours, at discharge time at 12 hours or 24 hours postoperative, and after discharge at 48 hours, 72 hours achieved through Telephone call with the patient. Patient satisfaction from cosmetic outcome was measured on 10 points scale. Divided into mild satisfied (1-3 points), moderate (4-7)and highly satisfied (8-10 points) at the second postoperative visit at 30 days postoperative, after 3 months and after 6 months, based on patient question to rate it, mild satisfaction: 1-3, moderate satisfaction:4-7 and highly satisfied: from 8-10

    Time frame: 3 years

07

Study locations

3 of 4 sites recruiting
  • Zagazig University hospitals
    Zagazig, Outside USA 12345, Egypt
    Recruiting
  • Zagazig University hospitals
    Zagazig, Outside USA 12345, Egypt
    Completed
  • Saudi German hospital
    Riyadh, Outside USA 11671, Saudi Arabia
    Recruiting
  • Saudi german hospital
    Riyadh, 11671, Saudi Arabia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — data can be shared through the publisher and all authers

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04836598
Lead sponsor
Zagazig University
Responsible party
Bassem Mohamed Sieda (assistant professor of general surgeryt, Zagazig University) — Principal investigator
First posted
Apr 8, 2021
Start date
Nov 30, 2016
Primary completion
Apr 20, 2021 (estimated)
Completion
Apr 30, 2021 (estimated)
Last update
Apr 8, 2021

Study contacts

Bassem M Sieda, professor
Contact
drbassemmostafa@yahoo.com
0541900039
Bassem M Sieda, professor
Contact
drbassemmostafa@yahoo.com
Bassem M Sieda, professor
study chair · 1975

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion